The effect of alendronate on resorption of the alveolar bone following tooth extraction

International Journal of Oral and Maxillofacial Surgery

Volumn 33, Issue 3, 2004, Pages 286-293

  Altundal, Hatice ^a   Guvener O ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Alendronate; Bone resorption; Extraction; Rat

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM; CREATININE; PHOSPHATE; SODIUM CHLORIDE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ALVEOLAR BONE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE TISSUE; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CELL COUNT; CONTROLLED STUDY; CREATININE URINE LEVEL; HAVERSIAN CANAL; HISTOPATHOLOGY; MALE; MANDIBLE; MOLAR TOOTH; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHOSPHATE BLOOD LEVEL; RAT; TOOTH EXTRACTION;

EID: 2342585998     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1006/ijom.2002.0472     Document Type: Article

References (62)

1. Astrom E, Soderhall S. Beneficial effect of long-term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002: 86: 356-364.
2. Atwood DA. Reduction of residual ridge: a major oral disease entity. J Prosthet Dent 1971: 26: 266-279.
3. Atwood DA. Postextraction changes in the adult mandible as illustrated by microradiographs of midsagittal sections and serial cephalometric roentgenograms. J Prosthet Dent 1963: 13: 810-824.
4. Balena R, Markatos A, Seedor JG, Gentile M, Stark C, Peter CP, Rodan GA. Long-term safety of the amino-bisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 1996: 276: 277-283.
5. Becker BE, Becker W, Ricci A, Geurs N. A prospective clinical trial of endosseous screw-shaped implants placed at the time of tooth extraction without augmentation. J Periodontol 1998: 69: 920-926.
6. Bettica P, Bevilacqua M, Vago T, Masino M, Cucinotta E. Short-term variations in bone remodeling biochemical markers: cyclical etidronate and alendronate effects compared. J Clin Endocrinol Metab 1997: 82: 3034-3039.
7. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000: 71: 1236-1240.
8. Boivin G, Meunier PJ. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2002: 2: 538-543.
9. Dunford JE, Ebetino FH, Rogers MJ. The mechanism of inhibition of farnesyl diphosnate synthase by nitrogen-containing bisphosphonates. Bone 2002: 30: 40.
10. Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term Risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 2002: 31: 620-625.
11. Fleich H. Bisphosphonates in osteoporosis: An introduction. Osteoporos Int 1993: 3: 3-5.
12. Fleisch H. Bisphosphonates-history and experimental basis. Bone 1987: 8: 23-28.
13. Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int 1993: 2: 15-22.
14. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekkar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: Effect of raloxifene HCI tamoxifen, estrogen, and alendronate. Bone 1996: 18: 621-627.
15. Frost MH. The biology of fracture healing: An overview for clinicians. Part I. Clin Orthop 1989: 248: 283-293.
16. Frost MH. The biology of fracture healing: An overview for clinicians. Part II. Clin Orthop 1989: 48: 294-309.
17. Hanne E, Sonis S, Gallagher G, Adwood D. Preservation of alveolar ridge with hydroxyapatite-collagen implants in rats. J Prosthet Dent 1988: 60: 729-734.
18. Hu JH, Ding M, Soballe K, Bechtold JE, Danielsen CC, Day JS, Hvid I. Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone 2002: 31: 591-597.
19. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995: 10: 1478-1487.
20. Igarashi K, Mitani H, Adachi H, Shinoda H. Anchorage and retentive effects of a bisphosphonate (AHBuBP) on tooth movement in rats. Am J Orthod Dentofacial Orthop 1994: 106: 279-289.
21. Igarashi K, Adachi H, Mitani H, Shinoda H. Inhibitory effect of the topical administration of a bisphosphonate (Risedronate) on root resorption incident to orthodontic tooth movement in rats. J Dent Res 1996: 75: 1644-1649.
22. Jahangari L, Devlin H, Ting K, Nishimura I. Current perspectives in residual ridge remodelling and its clinical implications: A review. J Prosthet Dent 1998: 80: 234-237.
23. Jeal W, Barradell LB, Mctavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 1997: 53: 415-434.
24. Kanis JA, Gertz BJ, Sibger F, Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 1995: 5: 1-13.
25. Kaynak D, Meffert R, Günhan M, Günhan O, Ozkaya O. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol 2000: 71: 790-796.
26. Kayou L, Sugiyama H, Imoto S, Tanne K. Effects of bisphosphonate on the remodeling of rat sagittal suture after rapid expansion. Angle Orthod 2001: 71: 265-273.
27. Khan SA, Vasikaran S, McCloskey EV, Beneton MN, Rogers S, Coulton L, Orgee J, Coombes G, Kanis JA. Alendronate in the treatment of Paget's disease of bone. Bone 1997: 20: 263-271.
28. Lafage M H, Balene R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan GA. Comparison of alendronate and sodium flouride effect on cancellous and cortical bone in minipigs. J Clin Invest 1995: 95: 2127-2133.
29. Lekowic V, Camargo PM, Klokkevold P, Weinlaender M, Kenney EB, Dimitrijevic B, Nedic M. Preservation of alveolar bone in extraction sockets using bioabsorable membranes. J Periodontol 1998: 69: 1044-1049.
30. 3H-Etidronate in rat and mouse bones. Bone 1996: 19: 281-290.
31. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000: 15: 613-620.
32. +-adenosine triphosphatase in a Japanese patient with infantile malignant osteopetrosis. Bone 2002: 28: 609-616.
33. McClung MR. Current bone mineral density data on bisphophonates in post-menopausal osteoporosis. Bone 1996: 19: 195-198.
34. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003: 32: 253-271.
35. Myoung H, Park JY, Choung PH. Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats. J Periodontal Res 2001: 36: 244-251.
36. Nancollas GH, Mangood AH, Gaafar EM, Wu W, Ebetino FH, Phipps RJ, Russell RGG. Mineral binding affinities of bisphosphonates. Bone 2002: 30: 42.
37. +-ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res 1997: 12: 1116-1123.
38. Ortega AJJ, Saldago SNC. Preprosthetic surgery: prevention of the alveolar process using retained tooth roots. Pract Odontol 1991: 12: 13-15.
39. Owens JM, Fuller K, Chambers TJ. Osteoclast activation: Potent inhibition by the bisphosphonate alendronate through a nonresorptive mechanism. J Cell Physiol 1997: 172: 79-86.
40. Plotkin LL, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999: 104: 1363-1374.
41. Ravn P, Neugebauer G, Christiansen C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002: 30: 320-324.
42. Reddy MS, Weatherford TW, Smith CA, West BD, Jeffcoat MK, Jacks TM. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol 1995: 66: 211-217.
43. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JK, Jaeger P, Body JJ, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002: 346: 653-661.
44. Rodan JA, Fleisch HA. Bisphosphonate: Mechanism of action. J Clin Invest 1996: 97: 2692-2696.
45. Rodan GA. Bone mass homeostasis and bisphosphonate action. Bone 1997: 20: 1-4.
46. Roschger P, Fratzl P, Klaushofer K, Rodan G. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 1997: 20: 393-397.
47. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993: 91: 2004-2011.
48. Sass DA, Bowman AR, Yuan Z, Ma Y, Jee WSS, Epstein S. Alendronate prevents cyclosporin A induced osteopenia in the rat. Bone 1997: 21: 65-70.
49. Shafer WG, Hine MK, Levy BM. A Textbook of Oral Surgery. Philadelphia: W.B. Saunders 1974: 550-553.
50. Shimizu M, Sasaki T, Ishihara A, Furuya R, Kawawa T. Bone wound healing after maxillary molar extraction in ovariectomized aged rats. J Electron Microsc (Tokyo) 1998: 47: 517-526.
51. Silver IA, Murrills RJ, Etherington DJI. Microelectrode studies on the acid micromovement beneath adherent macrophages and osteoclasts. Exp Cell Res 1988: 175: 266-276.
52. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA, Reda JRC, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996: 81: 961-967.
53. +-ATPase in incorporation of risedronate into osteoclasts. Bone 2003: 32: 341-349.
54. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996: 101: 488-501.
55. Van Beek ER, Löwik CWGM, Papapoulos SE. Effect of alendronate treatment on the osteoclastogenic potential of bone marrow cells in mice. Bone 1997: 20: 335-340.
56. Van Beek ER, Löwik CWGM, Papalous SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranyl-geranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002: 30: 64-70.
57. Warita H, Kirino Y, Kurihara S, Ohya K. Effects of local injection with bisphosphonate (HEBT) on experimental tooth movement. J Jpn Orthod Soc 1992: 51: 292-301.
58. Weinreb M, Quartuccio H, Seedor JG, Aufdemorte TB, Brunsvold M, Chaves E, Kornman KS, Rodan GA. Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodontal Res 1994: 29: 35-40.
59. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002: 109: 1041-1048.
60. Wiesen M, Kitzis R. Preservation of the alveolar ridge at implant sides. Periodontol Clin Investig 1998: 20: 17-20.
61. Williams RC, Jeffcoat MK, Howell TH, Rolla A, Stubbs D, Teoh KW, Reddy MS, Goldhaber P. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 1989: 60: 485-490.
62. Yaffe A, Izitkovich M, Earon Y, Alt I, Lilow R, Binderman I. Local delivery of an amino biphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats. J Periodontol 1997: 68: 884-889.